Screening, Diagnosis and Staging of Lung Cancer

Dear Colleagues,

Lung cancer is the leading cause of cancer-related deaths and represents a significant health burden worldwide. Its well-established association with smoking has led to secondary prevention interventions (screening) of high-risk populations, defined by age and smoking history. Although such screening programs have been associated with a significant reduction in lung-cancer related mortality, their incorporation in national screening programs is not yet universal. It should be noted that despite the impressive advances of immunotherapy and targeted therapies in the therapeutics of lung cancer, the prognosis of advanced stages is still dismal, highlighting the need of early detection that would permit curative therapeutic approaches. 

Moreover, the optimal diagnostic and staging procedure of lung cancer is of utmost importance, since it shapes the overall oncological management. In particular, invasive procedures of mediastinal staging are recommended in non-metastatic stages due to their higher sensitivity and specificity compared to imaging. Importantly, the establishment of lung cancer reference centers with a multidisciplinary approach with all specialists who are involved in the management of lung cancer should be a priority.

The aim of this Special Issue is to encompass a broad spectrum of topics related to the screening, diagnosis and staging of lung cancer. We welcome original research, review articles, clinical trials, and perspectives. We are looking forward to your contributions!

Dr. Ioannis Gkiozos
Dr. Andriani G. Charpidou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• screening lung cancer
• diagnosis lung cancer
• staging lung cancer
• clinical trial
• high-risk populations
• lung-cancer related mortality
• oncological management